Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema

NCT04464694 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT04464694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2020
Completion date
June 1, 2022
Enrollment
142 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, proliferative diabetic retinopathy